Overview
Lennox-Gastaut syndrome (LGS) is a severe childhood-onset developmental and epileptic encephalopathy characterized by multiple seizure types, including atypical absence, tonic, and atonic seizures, along with cognitive and behavioral impairments 16.Diagnosis
Multiple seizure types (atypical absence, tonic, atonic) 16
Specific EEG patterns with frequent slow spike-and-wave discharges 16
Significant cognitive impairment and behavioral issues 16
Imaging studies (CT/MRI) may show diffuse cerebral atrophy or other abnormalities in some cases 7Management
First-line treatments:
- Clonazepam 1
- Clobazam 1
Adjunctive treatments:
- Felbamate 1
- Lamotrigine 1
- Topiramate 1
- Rufinamide 1
- Cannabidiol 1
- Fenfluramine 1
- Valproate (off-label) 1
Non-pharmacological approaches:
- Ketogenic diet 3
- Consideration of music therapy (e.g., Mozart effect) for seizure reduction 5Special Populations
Pediatrics: Rufinamide use in pediatric patients highlights psychological and neurological adverse events 2
Comorbidities: Dysphagia development correlates with poor seizure outcomes and additional cognitive decline; intensive care management may be required 4Key Recommendations
Initiate treatment with clonazepam or clobazam as first-line options for LGS (Evidence: Strong 1)
Consider adjunctive therapies such as felbamate, lamotrigine, topiramate, rufinamide, cannabidiol, and fenfluramine based on individual response and tolerability (Evidence: Moderate 1)
Monitor for adverse effects, particularly neurological and psychological symptoms in pediatric patients treated with rufinamide (Evidence: Moderate 2)
Evaluate and manage dysphagia proactively in patients with LGS due to its association with poor seizure outcomes and increased medical care needs (Evidence: Moderate 4)
Explore non-pharmacological interventions like the ketogenic diet and potentially music therapy for seizure control (Evidence: Weak 35)References
1 Samanta D, Bhalla S, Bhatia S, Fine AL, Haridas B, Karakas C et al.. Antiseizure medications for Lennox-Gastaut Syndrome: Comprehensive review and proposed consensus treatment algorithm. Epilepsy & behavior : E&B 2025. link
2 Wang L, Gui J, Zhang X, Tian B, Meng L, Liu J et al.. Disproportionality analysis of the safety profile of rufinamide in the real world: an evaluation of the FDA Adverse Event Reporting System database. Expert opinion on drug safety 2025. link
3 Farrell K. Drug therapy in Lennox-Gastaut syndrome. Advances in experimental medicine and biology 2002. link
4 Ogawa K, Kanemoto K, Ishii Y, Koyama M, Shirasaka Y, Kawasaki J et al.. Long-term follow-up study of Lennox-Gastaut syndrome in patients with severe motor and intellectual disabilities: with special reference to the problem of dysphagia. Seizure 2001. link
5 Hughes JR, Fino JJ, Melyn MA. Is there a chronic change of the "Mozart effect" on epileptiform activity? A case study. Clinical EEG (electroencephalography) 1999. link
6 Niedermeyer E. The Lennox-Gastaut syndrome and its frontiers. Clinical EEG (electroencephalography) 1986. link
7 Zimmerman AW, Niedermeyer E, Hodges FJ. Lennox-Gastaut syndrome and computerized axial tomography findings. Epilepsia 1977. link